Soleno Therapeutics (SLNO) has disclosed a new risk, in the Accounting & Financial Operations category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Soleno Therapeutics faces significant business risks as it embarks on generating product revenue, particularly with its recent commercialization of VYKAT XR. The company’s ability to achieve and maintain profitability is contingent upon successfully navigating a multitude of challenges, including establishing a robust commercial organization, achieving market acceptance, and securing reliable manufacturing and distribution partnerships. Additionally, Soleno must overcome regulatory hurdles, protect its intellectual property, and manage potential increases in expenses due to unforeseen regulatory demands or clinical trial requirements. The uncertainty surrounding these factors poses a substantial risk to Soleno’s financial stability and operational continuity.
The average SLNO stock price target is $117.36, implying 150.39% upside potential.
To learn more about Soleno Therapeutics’ risk factors, click here.